The comorbidity and co-medication profile of patients with progressive supranuclear palsy.

Comorbidities Drug–drug interactions Polypharmacy Progressive supranuclear palsy

Journal

Journal of neurology

ISSN: 1432-1459

Titre abrégé: J Neurol

Pays: Germany

ID NLM: 0423161

Informations de publication

Date de publication:
06 Oct 2023

Historique:

received: 23 08 2023

accepted: 14 09 2023

revised: 12 09 2023

medline: 7 10 2023

pubmed: 7 10 2023

entrez: 6 10 2023

Statut: aheadofprint

Résumé

Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®. In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions. PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

Sections du résumé

BACKGROUND BACKGROUND

Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.

OBJECTIVES OBJECTIVE

To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.

METHODS METHODS

Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®.

RESULTS RESULTS

In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.

CONCLUSIONS CONCLUSIONS

PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

Identifiants

DOI: 10.1007/s00415-023-12006-4 PMID: 37803149

pubmed: 37803149

doi: 10.1007/s00415-023-12006-4

pii: 10.1007/s00415-023-12006-4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288

pubmed: 9371909 doi: 10.1212/WNL.49.5.1284

Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766

pubmed: 25370486 doi: 10.1002/mds.26054

Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU (2021) Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176

pubmed: 33967937 pmcid: 8100604 doi: 10.3389/fneur.2021.637176

Zella MAS, Bartig D, Herrmann L, Respondek G, Höglinger G, Gold R, Woitalla D, Krogias C, Tönges L (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. J Clin Med 9:E2454

doi: 10.3390/jcm9082454

Rabadia SV, Litvan I, Juncos J et al (2019) Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166–170

pubmed: 31420308 doi: 10.1016/j.parkreldis.2019.07.036

Lamb R, Rohrer JD, Lees AJ, Morris HR (2016) Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol 18:42

pubmed: 27526039 pmcid: 4985534 doi: 10.1007/s11940-016-0422-5

Rowe JB, Holland N, Rittman T (2021) Progressive supranuclear palsy: diagnosis and management. Pract Neurol 21:376–383

pubmed: 34215700 pmcid: 8461411 doi: 10.1136/practneurol-2020-002794

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? a systematic review of definitions. BMC Geriatr 17:230

pubmed: 29017448 pmcid: 5635569 doi: 10.1186/s12877-017-0621-2

Midão L, Giardini A, Menditto E, Kardas P, Costa E (2018) Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr 78:213–220

pubmed: 30015057 doi: 10.1016/j.archger.2018.06.018

Pazan F, Wehling M (2021) Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med 12:443–452

pubmed: 33694123 pmcid: 8149355 doi: 10.1007/s41999-021-00479-3

Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918

pubmed: 17867728 doi: 10.2165/00002018-200730100-00009

Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17:1185–1196

pubmed: 30540223 doi: 10.1080/14740338.2018.1546841

Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML (2017) Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc 57:729-738.e10

doi: 10.1016/j.japh.2017.06.002

Piot I, Schweyer K, Respondek G et al (2020) The progressive supranuclear palsy clinical deficits scale. Mov Disord 35:650–661

pubmed: 31951049 doi: 10.1002/mds.27964

Respondek G, Höglinger GU (2021) DescribePSP and ProPSP: German multicenter networks for standardized prospective collection of clinical data, imaging data, and biomaterials of patients with progressive supranuclear palsy. Front Neurol 12:644064

pubmed: 34113306 pmcid: 8186498 doi: 10.3389/fneur.2021.644064

Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord 32:853–864

pubmed: 28467028 pmcid: 5516529 doi: 10.1002/mds.26987

Grimm M-J, Respondek G, Stamelou M et al (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34:1228–1232

pubmed: 30884545 pmcid: 6699888 doi: 10.1002/mds.27666

Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343–345

pubmed: 32258239 pmcid: 7111582 doi: 10.1002/mdc3.12921

Hecht T, Bundscherer AC, Lassen CL, Lindenberg N, Graf BM, Ittner K-P, Wiese CHR (2015) The expenditure of computer-related worktime using clinical decision support systems in chronic pain therapy. BMC Anesthesiol 15:113

pubmed: 26231078 pmcid: 4521352 doi: 10.1186/s12871-015-0094-9

Seidling HM, Klein U, Schaier M, Czock D, Theile D, Pruszydlo MG, Kaltschmidt J, Mikus G, Haefeli WE (2014) What, if all alerts were specific - estimating the potential impact on drug interaction alert burden. Int J Med Inform 83:285–291

pubmed: 24484781 doi: 10.1016/j.ijmedinf.2013.12.006

Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, Walter-Sack I, Haefeli WE, Encke J (2010) Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 36:665–672

pubmed: 20143221 doi: 10.1007/s00134-010-1778-8

Sieber CC (2007) The elderly patient–who is that? Internist (Berl) 48(1190):1192–1194

Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11:459–463

pubmed: 16154793 doi: 10.1016/j.parkreldis.2005.06.003

Tamayo T, Brinks R, Hoyer A, Kuß OS, Rathmann W (2016) The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int 113:177–182

pubmed: 27118665 pmcid: 4850517

Busch MA, Schienkiewitz A, Nowossadeck E, Gößwald A (2013) Prävalenz des Schlaganfalls bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 56:656–660

doi: 10.1007/s00103-012-1659-0

Zhang Y, Moran AE (2017) Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension 70:736–742

pubmed: 28847890 doi: 10.1161/HYPERTENSIONAHA.117.09801

Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev 64:272–287

pubmed: 26969101 doi: 10.1016/j.neubiorev.2016.03.005

Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C (2020) Understanding the links between cardiovascular disease and Parkinson’s disease. Mov Disord 35:55–74

pubmed: 31483535 doi: 10.1002/mds.27836

Tublin JM, Adelstein JM, Del Monte F, Combs CK, Wold LE (2019) Getting to the heart of Alzheimer Disease. Circ Res 124:142–149

pubmed: 30605407 pmcid: 6319653 doi: 10.1161/CIRCRESAHA.118.313563

Liu Y, Xue L, Zhang Y, Xie A (2020) Association between stroke and parkinson’s disease: a meta-analysis. J Mol Neurosci 70:1169–1176

pubmed: 32180111 doi: 10.1007/s12031-020-01524-9

Jecmenica Lukic M, Kurz C, Respondek G et al (2020) Copathology in progressive supranuclear palsy: does it matter? Mov Disord 35:984–993

pubmed: 32125724 doi: 10.1002/mds.28011

Leszek J, Sochocka M, Gąsiorowski K (2012) Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer’s disease. J Neurol Sci 323:25–32

pubmed: 23026534 doi: 10.1016/j.jns.2012.09.010

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

pubmed: 1564476 pmcid: 1014720 doi: 10.1136/jnnp.55.3.181

Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe C-U (2022) Diabetes, glycated hemoglobin (HbA1c), and neuroaxonal damage in Parkinson’s Disease (MARK-PD Study). Mov Disord 37:1299–1304

pubmed: 35384057 doi: 10.1002/mds.29009

Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G (2021) Diabetes mellitus and Parkinson’s Disease: a systematic review and meta-analyses. JPD 11:1585–1596

pubmed: 34486987 doi: 10.3233/JPD-212725

Athauda D, Evans J, Wernick A et al (2022) The impact of type 2 diabetes in Parkinson’s Disease. Mov Disord 37:1612–1623

pubmed: 35699244 pmcid: 9543753 doi: 10.1002/mds.29122

De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT (2018) Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology 91:e139–e142

pubmed: 29898968 doi: 10.1212/WNL.0000000000005771

Aamodt WW, Waligorska T, Shen J et al (2021) Neurofilament light chain as a biomarker for cognitive decline in Parkinson Disease. Mov Disord 36:2945–2950

pubmed: 34480363 pmcid: 8688198 doi: 10.1002/mds.28779

Niemann L, Lezius S, Maceski A, Leppert D, Englisch C, Schwedhelm E, Zeller T, Gerloff C, Kuhle J, Choe C-U (2021) Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson’s disease (MARK-PD). Parkinsonism Relat Disord 90:44–48

pubmed: 34352610 doi: 10.1016/j.parkreldis.2021.07.028

Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-Blind Clin Trial Front Aging Neurosci 8:108

Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc 60:916–921

pubmed: 22458300 doi: 10.1111/j.1532-5415.2012.03916.x

Kim B, Backus C, Oh S, Feldman EL (2013) Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer’s disease. J Alzheimers Dis 34:727–739

pubmed: 23254634 pmcid: 5545747 doi: 10.3233/JAD-121669

Huang R, Tian S, Zhang H, Zhu W, Wang S (2020) Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro. Brain Res Bull 156:76–85

pubmed: 31931119 doi: 10.1016/j.brainresbull.2020.01.006

Elman-Shina K, Efrati S (2022) Ischemia as a common trigger for Alzheimer’s disease. Front Aging Neurosci 14:1012779

pubmed: 36225888 pmcid: 9549288 doi: 10.3389/fnagi.2022.1012779

Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L (2017) Mixed dementia: a review of the evidence. Dement Neuropsychol 11:364–370

pubmed: 29354216 pmcid: 5769994 doi: 10.1590/1980-57642016dn11-040005

Pluta R, Januszewski S, Czuczwar SJ (2021) Brain ischemia as a prelude to Alzheimer’s Disease. Front Aging Neurosci 13:636653

pubmed: 33679381 pmcid: 7931451 doi: 10.3389/fnagi.2021.636653

Kapasi A, Yu L, Petyuk V, Arfanakis K, Bennett DA, Schneider JA (2022) Association of small vessel disease with tau pathology. Acta Neuropathol 143:349–362

pubmed: 35044500 pmcid: 8858293 doi: 10.1007/s00401-021-02397-x

Kapasi A, Leurgans SE, Arvanitakis Z, Barnes LL, Bennett DA, Schneider JA (2021) Aβ (Amyloid Beta) and Tau Tangle Pathology Modifies the Association between small vessel disease and cortical microinfarcts. Stroke 52:1012–1021

pubmed: 33567873 pmcid: 7902459 doi: 10.1161/STROKEAHA.120.031073

Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86:27–68

pubmed: 28498720 doi: 10.1146/annurev-biochem-061516-045115

Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273:1331–1349

pubmed: 16689923 doi: 10.1111/j.1742-4658.2006.05181.x

Welch WJ (2004) Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15:31–38

pubmed: 15036204 doi: 10.1016/j.semcdb.2003.12.011

Brehme M, Voisine C, Rolland T et al (2014) A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep 9:1135–1150

pubmed: 25437566 pmcid: 4255334 doi: 10.1016/j.celrep.2014.09.042

McKinnon C, Tabrizi SJ (2014) The ubiquitin-proteasome system in neurodegeneration. Antioxid Redox Signal 21:2302–2321

pubmed: 24437518 doi: 10.1089/ars.2013.5802

Dias BM, Santos FSD, Reis AMM (2019) Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: cross-sectional study. Sao Paulo Med J 137:369–378

pubmed: 31691770 pmcid: 9744019 doi: 10.1590/1516-3180.2019.013405072019

Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna) 128:49–60

pubmed: 33263172 doi: 10.1007/s00702-020-02276-x

Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU (2017) Drug safety analysis in a real-life cohort of Parkinson’s disease patients with polypharmacy. CNS Drugs 31:1093–1102

pubmed: 29139041 doi: 10.1007/s40263-017-0478-0

Sánchez-Arenas R, Sánchez-García S, García-Peña C, García-Gonzàlez JJ, Rivera-García BE, Juárez-Cedillo T (2012) Drug-drug interactions at hospital admission in geriatric patients in a single facility: a retrospective study. Int J Clin Pharmacol Ther 50:426–430

pubmed: 22541743 doi: 10.5414/CP201551

Hong WK, Mauer P, Hochman R, Caslowitz JG, Paraskos JA (1974) Amitriptyline cardiotoxicity. Chest 66:304–306

pubmed: 4423835 doi: 10.1378/chest.66.3.304

Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D (2010) Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 19:881–888

pubmed: 20652862 doi: 10.1002/pds.2016

van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MCJM (2010) Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 33:1003–1014

pubmed: 20925438 doi: 10.2165/11536840-000000000-00000

Schwartz M, Patel M, Kazzi Z, Morgan B (2008) Cardiotoxicity after massive amantadine overdose. J Med Toxicol 4:173–179

pubmed: 18821491 pmcid: 3550039 doi: 10.1007/BF03161197

Prieto-García L, Pericacho M, Sancho-Martínez SM, Sánchez Á, Martínez-Salgado C, López-Novoa JM, López-Hernández FJ (2016) Mechanisms of triple whammy acute kidney injury. Pharmacol Ther 167:132–145

pubmed: 27490717 doi: 10.1016/j.pharmthera.2016.07.011

Harężlak T, Religioni U, Szymański FM, Hering D, Barańska A, Neumann-Podczaska A, Allan M, Merks P (2022) Drug interactions affecting kidney function: beware of health threats from triple whammy. Adv Ther 39:140–147

pubmed: 34845649 doi: 10.1007/s12325-021-01939-9

Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346:e8525

pubmed: 23299844 pmcid: 3541472 doi: 10.1136/bmj.e8525

Clark HM, Stierwalt JAG, Tosakulwong N, Botha H, Ali F, Whitwell JL, Josephs KA (2020) Dysphagia in progressive supranuclear palsy. Dysphagia 35:667–676

pubmed: 31676923 doi: 10.1007/s00455-019-10073-2

Thiyagalingam S, Kulinski AE, Thorsteinsdottir B, Shindelar KL, Takahashi PY (2021) Dysphagia in older adults. Mayo Clin Proc 96:488–497

pubmed: 33549267 doi: 10.1016/j.mayocp.2020.08.001

Moura CS, Prado NM, Belo NO, Acurcio FA (2012) Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 34:547–552

pubmed: 22535491 doi: 10.1007/s11096-012-9642-2